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Microbial protease-mediated disruption of the intestinal epithelium is a potential mechanism whereby a dysbiotic enteric micro-
biota can lead to disease. This mechanism was investigated using the colitogenic, protease-secreting enteric microbe Enterococ-
cus faecalis. Caco-2 and T-84 epithelial cell monolayers and the mouse colonic epithelium were exposed to concentrated condi-
tioned media (CCM) from E. faecalis V583 and E. faecalis lacking the gelatinase gene (gelE). The flux of fluorescein
isothiocyanate (FITC)-labeled dextran across monolayers or the mouse epithelium following exposure to CCM from parental or
mutant E. faecalis strains indicated paracellular permeability. A protease-activated receptor 2 (PAR2) antagonist and PAR2-defi-
cient (PAR2/) mice were used to investigate the role of this receptor in E. faecalis-induced permeability. Gelatinase (GelE)
purified from E. faecalis V583 was used to confirm the ability of this protease to induce epithelial cell permeability and activate
PAR2. The protease-mediated permeability of colonic epithelia from wild-type (WT) and PAR2/ mice by fecal supernatants
from ulcerative colitis patients was assessed. Secreted E. faecalis proteins induced permeability in epithelial cell monolayers,
which was reduced in the absence of gelE or by blocking PAR2 activity. Secreted E. faecalis proteins induced permeability in the
colonic epithelia of WT mice that was absent in tissues from PAR2/ mice. Purified GelE confirmed the ability of this protease
to induce epithelial cell permeability via PAR2 activation. Fecal supernatants from ulcerative colitis patients induced permeabil-
ity in the colonic epithelia of WT mice that was reduced in tissues from PAR2/ mice. Our investigations demonstrate that GelE
from E. faecalis can regulate enteric epithelial permeability via PAR2.
Apotential mechanism for the pathogenesis of inflammatorybowel diseases (IBD) and irritable bowel syndrome (IBS) in-
volves disruption of the intestinal epithelial barrier and exposure
of a genetically defective immune system to enteric microbial an-
tigens. Indeed, IBD and IBS patients exhibit a higher level of in-
testinal permeability than healthy controls (1–7). Additionally,
first-degree relatives of IBD patients display elevated levels of en-
teric permeability (8–10), suggesting that this abnormality is in-
dependent of inflammation. Consistent with this hypothesis are
animal models of colitis that use chemical disruption of the epi-
thelial barrier with trinitrobenzene sulfonic acid, dextran sodium
sulfate, or nonsteroidal anti-inflammatory drugs (NSAIDs) to
elicit inflammation (11). Further, disruption of the intestinal ep-
ithelial barrier by exposure of susceptible patients to NSAIDs
(blockers of prostaglandin synthesis) is a risk factor for intestinal
inflammation (12).
Enteric proteases can act broadly as catalysts of protein degra-
dation or specifically as selective agents that control physiological
processes (13). Additionally, these enzymes can disrupt mucosal
barriers and modulate the host immune response (14). Proteases
can mediate their activity on mammalian cells through the activa-
tion of protease-activated receptors (PARs). The PAR family has
four members, PARs 1 to 4 (15–19). These are transmembrane
domain G-protein-coupled receptors that mediate multiple re-
sponses to external stimuli, such as hemostasis, thrombosis, and
inflammation. PARs are activated through proteolytic cleavage of
the extracellular N-terminal component of the receptor, unmask-
ing a tethered peptide ligand residue that binds with another re-
gion of the receptor, causing a conformational change (20). Ex-
cept for one study, reporting that PAR2 activation results in
decreased colonic inflammation (21), the majority of investiga-
tions have found that activating PAR isoforms increases intestinal
permeability and inflammation (22–25). Indeed, fecal proteases
from ulcerative colitis (UC) patients have been shown to induce
intestinal permeability in a PAR-dependent manner (24). How-
ever, it is unclear whether fecal protease-induced intestinal per-
meability is of mammalian or bacterial origin. Accumulating evi-
dence shows that endogenous enteric microbes produce proteases
that possess the ability to disrupt the epithelial barrier (26, 27).
These commensal proteases may be involved in the pathogenesis
of intestinal diseases in the context of a genetically predisposed
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host or an intestinal microbial dysbiosis. The interaction between
the enteric microbiota and PARs may present a unique mecha-
nism in which a microbial dysbiosis is associated with intestinal
diseases via protease-mediated enteric permeability.
Enterococcus faecalis is a constituent of the normal intestinal
microbiota that can induce intestinal inflammation in the inter-
leukin 10 (IL-10)-deficient mouse model of colitis (28). E. faecalis
secretes two dominant proteases, gelatinase (GelE) and serine
protease (SprE) (29), making this species an ideal model with
which to investigate bacterial protease-mediated enteric permea-
bility and inflammation. Seminal work has demonstrated that E.
faecalis-induced intestinal inflammation is associated with enteric
permeability mediated by GelE degradation of an epithelial junc-
tional protein (E-cadherin) (27). Here we suggest a novel mecha-
nism by which E. faecalis can induce intestinal inflammation via
enteric permeability mediated by GelE activation of PAR2.
MATERIALS AND METHODS
Bacterial strains, cell culture, and preparation of CCM. E. faecalis V583
(originally isolated from infected human blood) (30) was used in our
study. The gelE isogenic mutant was generated as described previously
(29). Bacteria were cultivated in brain heart infusion (BHI) medium (BD,
Sparks, MD) at 37°C under aerobic conditions. For the preparation of
concentrated conditioned media (CCM), bacterial culture supernatants
from overnight cultures were concentrated using the Centriprep filter
system (Millipore, Carrigtwohill, Cork, Ireland) with an exclusion size of
10 kDa. The abilities of parental E. faecalis V583 and mutant E. faecalis
CCM to degrade casein were tested using BHI agar containing 2.5% skim
milk with a methodology similar to that of previously described work
(31). Briefly, parental or mutant E. faecalis cells were cultured overnight at
37°C; then 20 l of this culture was spotted onto skim milk agar plates and
was incubated overnight at 37°C. Additionally, 20 l of parental or mu-
tant CCM was pipetted directly onto skim milk agar plates and was incu-
bated overnight at 37°C. A zone of clearing surrounding E. faecalis cells or
CCM indicated caseinolytic activity. The Caco-2 and T-84 human colonic
epithelial cell lines were cultured in Dulbecco’s modified Eagle medium
(DMEM; Gibco-Invitrogen) supplemented with 10% heat-inactivated fe-
tal bovine serum (Sigma-Aldrich), 1% L-glutamine (Gibco-Invitrogen),
and 1% penicillin-streptomycin (Gibco-Invitrogen) and were grown at
37°C in a 5% CO2 humidified incubator. For epithelial cell monolayer
development, 2  105 Caco-2 or T-84 cells were seeded into transwell
plates with a pore size of 0.4 or 3.0 M, respectively, and were cultured
under standard conditions. Monolayers were cultured until tight junc-
tions (T-Js) formed between cells, as determined by transepithelial elec-
trical resistance (TEER) measurements as described previously (32).
Exposure of epithelial cells to E. faecalis CCM and monolayer per-
meability assay. Caco-2 and T-84 cell monolayers were exposed to CCM
from either E. faecalis V583 or E. faecalis gelE. Caco-2 cell monolayers
were exposed to CCM apically, whereas T-84 cell monolayers were ex-
posed to CCM basally, since PARs are expressed basolaterally in this cell
line (33). After 20 h of CCM exposure, fluorescein isothiocyanate (FITC)-
labeled dextran (50 ng/ml) was added to the upper chamber of the trans-
well, and monolayers were incubated for a further 4 h. Fluorescence was
measured in the upper and lower chambers of the transwell plates using a
fluorometer (SLM Aminco SPF 500; SLM Instruments, Urbana, IL) at an
excitation wavelength of 485 nm and an emission wavelength of 530 nm to
determine the percent flux of FITC-dextran across the monolayer. The
PAR2 antagonist (FSLLRY-NH2; Tocris, Bristol, United Kingdom) was
incubated with Caco-2 and T-84 cell monolayers for 24 h prior to expo-
sure to experimental conditions at final concentrations of 5 and 20 M,
respectively.
Ex vivo epithelial permeability. The ex vivo permeability of colonic
tissue from wild-type (WT) C57BL/6 mice and PAR2/ mice was deter-
mined using Ussing chambers as described previously (34). Briefly, distal
colonic tissue sections were mounted between Lucite rings (aperture di-
ameter, 2 mm; square area, 0.0314 cm2) in mini-Ussing chambers and
were bathed on both sides with normal Ringer’s solution. The flux was
determined by adding FITC-dextran (50 ng/ml) to the bath exposed to the
mucosal side of the tissue sample. An initial reading from the mucosal
bath was taken, and the serosal bath was sampled at baseline and 2 h later.
Samples were read for the presence of FITC-dextran using a fluorometer
(SLM Aminco SPF 500; SLM Instruments, Urbana, IL) at an excitation
wavelength of 485 nm and an emission wavelength of 530 nm. The flux as a
percentage of the initial FITC-dextran concentration was calculated as (fluo-
rescence in the serosal samples)/(fluorescence in the luminal bath)  100.
Human fecal samples were collected from UC patients (n  7) in the
IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv
Medical Center, Tel Aviv, Israel. Upon collection, each sample was ho-
mogenized and frozen at 80°C. Fecal supernatants from all samples (n 
7) were generated as described previously (24, 35). Briefly, 500 mg of fecal
material was thawed on ice. Four milliliters of a sterile 0.9% NaCl solution
was added to each sample. All samples were homogenized using a sonica-
tor (Sonic Dismembrator, set at level 10; Fisher Scientific) on ice. The
sonicated mixture was then centrifuged for 10 min at 4,500 rpm at 4°C.
Fecal supernatants were transferred to a syringe and were passed through
a filter (0.45 M), and pellets were discarded. The resulting fecal super-
natants were stored at 80°C. Human experiments were approved by the
local IRB at the Tel Aviv Medical Center.
Purification of gelatinase and Western blot analysis. Gelatinase
(GelE) secreted by E. faecalis V583 was partially purified using methods
described by Hancock and Perego (36). The cell-free culture fluid of a
2-liter overnight culture of E. faecalis V583 grown in Todd-Hewitt broth
was collected by centrifugation (at 5,000  g, 4°C for 30 min). The con-
ditioned medium was incubated overnight at 4°C with constant stirring,
and ammonium sulfate was then added gradually to a final saturation of
60%. The resulting precipitate was collected by centrifugation (at 27,500
 g, 4°C for 30 min) and was resuspended in 200 ml of 200 mM Tris-HCl,
5 mM CaCl2 (pH 7.6). The resuspended protein was filter sterilized (0.2
m) and was dialyzed (molecular weight cutoff [MWCO], 2,000) against
dialysis buffer (50 mM Tris-HCl, 5 mM CaCl2 [pH 7.6]). Dialysis was
performed at 4°C with constant stirring for 4 days with daily changes of
buffer. The dialyzed sample was then concentrated to a volume of 20 ml by
lyophilization using a VirTis Sentry Vacu Station 1SL system (SP Scien-
tific, Gardiner, NY). Purified protein was run on a 4- to 20% gradient SDS
gel (Bio-Rad Laboratories, Inc., Hercules, CA) to determine the sizes and
purities of precipitated proteins.
The protein sample was digested using the filter-aided sample prepa-
ration protocol (37), and the resulting peptides were analyzed by liquid
chromatography–tandem mass spectrometry (LC–MS-MS) as described
previously (38). The spectra were searched using Peaks Studio software
(version 7; Bioinformatics Solutions Inc.) with a downloaded UniProt/
Swiss-Prot protein database.
Caco-2 cells were seeded onto 6-well plates and were grown to conflu-
ence. The cells were then exposed to 100 l of purified GelE for 1 h. Total
cellular protein was extracted with a lysis buffer (50 mmol/liter Tris HCl,
150 mmol/liter NaCl, 40 mmol/liter EDTA, 1% NP-40 [pH 7.5] plus
Complete protease inhibitor cocktail [Roche, Indianapolis, IN]). Western
blotting using an anti-PAR2 antibody (ab138479; Abcam, Cambridge,
MA) and anti--actin (ICN601001; MP Biomedicals, Solon, OH) was
carried out as described previously (39).
Statistical analysis. Data are expressed as mean values  standard
errors (SE). Statistical examinations were performed using GraphPad
Prism (version 5.01) software. Data comparing more than two groups
were analyzed by one-way analysis of variance (ANOVA) with Tukey’s
multiple-comparison test. Data comparing two groups were analyzed
with the nonparametric Mann-Whitney test. A P value of 0.05 was con-
sidered statistically significant. Data are presented as the fold change in the
flux of FITC-dextran from that of the medium control or parental E.
faecalis strain V583 in Caco-2 and T-84 cell experiments and as the fold
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change in the flux of FITC-dextran from that of the control (phosphate-
buffered saline [PBS]) in Ussing chamber experiments.
RESULTS
E. faecalis V583 CCM exhibits caseinolytic activity that is elim-
inated in the absence of gelE. Seminal work has demonstrated the
ability of GelE secreted from E. faecalis to degrade casein (40). E.
faecalis V583 cells and CCM exhibited the ability to degrade casein
(Fig. 1A and B). Cells and CCM from E. faecalis lacking gelE
(gelE) failed to exhibit caseinolytic properties (Fig. 1A and B).
Importantly, these data demonstrate that GelE is active in CCM
from E. faecalis V583 and not in CCM from E. faecalis gelE.
E. faecalis V583 CCM induces permeability in epithelial cell
monolayers. To investigate the ability of E. faecalis-secreted pro-
teins to permeabilize the epithelial cell barrier, we exposed Caco-2
and T-84 cell monolayers to CCM from E. faecalis V583 and E.
faecalis gelE. Caco-2 cell monolayers exposed apically to E. faeca-
lis V583 CCM for 24 h exhibited a significant (P 	 0.0001) 3.2-fold
increase in permeability over the medium control (Fig. 2A). The
absence of gelE resulted in a significant decrease (P 	 0.0001) in E.
faecalis V583 CCM-mediated monolayer permeability (Fig. 2A).
Additionally, T-84 cell monolayers exposed basally to E. faecalis
V583 CCM for 24 h exhibited a significant (P 	 0.0001) 2.3-fold
increase in permeability over the medium control (Fig. 2B).
CCM-mediated permeability was mirrored by a loss of barrier
function, as determined by TEER (see Fig. S1 in the supplemental
material). Conversely, apical exposure of T-84 cell monolayers to
E. faecalis V583 CCM for 24 h did not impact permeability (see
Fig. S2 in the supplemental material). Since PARs are expressed
basolaterally and not apically on T-84 cell monolayers, this obser-
vation suggests the involvement of these receptors in CCM-medi-
ated permeability. In agreement with the results for Caco-2 cell
monolayers, the absence of gelE resulted in a significant decrease
(P 	 0.0001) in E. faecalis V583 CCM-mediated permeability of
T-84 cell monolayers (Fig. 2B). These results suggest that secreted
GelE is needed for E. faecalis V583 CCM-mediated monolayer
E. faecalis V583 
CCM 
E. faecalis ΔgelE 
CCM
PBS 
E. faecalis ΔgelE E. faecalis V583 
A 
B 
FIG 1 Deletion of gelE from E. faecalis V583 results in the loss of casein
degradation. E. faecalis V583, E. faecalis gelE, and CCM from the growth of
these strains were incubated overnight on agar plates containing 2.5% skim
milk. (A) The parental E. faecalis strain V583 exhibits caseinolytic activity,
while deletion of the gelE gene from E. faecalis V583 results in the loss of
caseinolytic activity. (B) CCM from the parental E. faecalis strain V583 exhibits
caseinolytic activity, while CCM from E. faecalis gelE exhibits no caseinolytic
activity. These observations were made consistently upon multiple incuba-
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FIG 2 Deletion of gelE from E. faecalis V583 reduces the permeability of
epithelial cell monolayers. (A) Caco-2 cell monolayers were incubated with
CCM from E. faecalis V583 (filled bars) or from E. faecalis lacking the gelE gene
(gelE) (shaded bars). The flux of FITC-dextran across Caco-2 cell monolay-
ers (indicative of paracellular permeability) was significantly greater when
monolayers were apically cultured with E. faecalis V583 CCM for 24 h than
with the medium control (open bars) (*, P 	 0.0001). The flux of FITC-
dextran across Caco-2 cell monolayers was significantly reduced to that of E.
faecalis V583 CCM when cultured with CCM from E. faecalis gelE for 24 h (*,
P 	 0.0001). (B) T-84 cell monolayers were incubated with CCM from E.
faecalis V583 or E. faecalis gelE. The flux of FITC-dextran across T-84 cell
monolayers was significantly greater when monolayers were basally cultured
with E. faecalis V583 CCM for 24 h than with the medium control (*, P 	
0.0001). The flux of FITC-dextran across T-84 cell monolayers was signifi-
cantly reduced to that of E. faecalis V583 CCM when cultured with CCM from
E. faecalis gelE for 24 h (*, P 	 0.0001). Each experimental group represents
at least 3 independent experiments with 2 technical replicates in each experi-
ment. Data are expressed as mean values  standard errors. Comparisons were
made using one-way ANOVA.
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permeability. Additionally, since gelatinase is one of many se-
creted proteases encoded in the E. faecalis V583 genome (41), and
since the elimination of this single protease from this organism
significantly reduces the ability of E. faecalis CCM to induce per-
meability in epithelial monolayers, we believe that not all pro-
teases secreted by this microbe can carry out this process.
Antagonism of PAR2 reduces the E. faecalis V583 CCM-in-
duced permeability of epithelial cell monolayers. To determine
whether the induction of permeability in Caco-2 and T-84 cell
monolayers by E. faecalis GelE acts via PAR2, we used an antago-
nist that has been reported to block PAR2 activation (42). A sig-
nificant decrease (P 	 0.0001) in the degree of permeability in-
duced by E. faecalis V583 CCM was found in Caco-2 cell
monolayers exposed to the PAR2 antagonist, while the PAR2 an-
tagonist alone exhibited no significant effect on monolayer barrier
permeability (Fig. 3). This reduction in E. faecalis V583 CCM-
induced permeability by a PAR2 antagonist was observed at a
range of concentrations (see Fig. S3A in the supplemental mate-
rial). No decrease in the degree of permeability induced by E.
faecalis V583 CCM was found in T-84 cell monolayers exposed to
the PAR2 antagonist; however, barrier stability was impacted, as
reflected by a change in TEER values (see Fig. S3B and C in the
supplemental material).
E. faecalis V583 CCM-induced permeability of the mouse
colonic epithelium is reduced in the absence of PAR2. The PAR2
antagonist used in this study is a peptide that binds to the PAR2
receptor and inhibits subsequent activation (42). Since this antag-
onist may exhibit nonspecific inhibition of PAR2 signaling, we
used the intestinal epithelia from PAR2/ mice to confirm the
role of this receptor in the induction of permeability by E. faecalis
V583 CCM. Indeed, a significant 2-fold increase (P 	 0.04) in
permeability was observed when the colonic epithelia from WT
mice were exposed to E. faecalis V583 CCM (Fig. 4). Additionally,
E. faecalis V583 CCM-induced permeability was not observed in
the colonic epithelia of mice lacking the PAR2 receptor. Interest-
ingly, the baseline permeabilities of the epithelia from WT and
PAR2/ mice did not differ when the absolute flux of FITC-
dextran across these barriers was analyzed (see Fig. S4 in the sup-
plemental material). These data confirm that secreted proteins
from E. faecalis are capable of inducing permeability in the mouse
colon via PAR2.
GelE purified from E. faecalis V583 induces permeability in
epithelial cell monolayers and activates PAR2. Although dele-
tion of the gelE gene from E. faecalis V583 resulted in decreased
CCM-mediated permeability of epithelial cell monolayers, the re-
moval of this gene may functionally impact the neighboring se-
creted protease, serine protease, which could potentially play a
role in this process. We therefore sought to purify GelE from E.
faecalis V583 in order to confirm the role of this protease in the
induction of epithelial cell permeability via PAR2. Using previ-
ously described methods to isolate GelE (36), we purified an ap-
proximately 38 kDa protein from E. faecalis V583 that exhibited
caseinolytic properties (Fig. 5A and B). The 38-kDa protein was
confirmed to be GelE following trypsin digestion and LC–MS-MS
(27 matching peptides with 48% coverage) (Fig. 5C). Purified
GelE induced permeability in Caco-2 and T-84 cell monolayers
(Fig. 6), demonstrating that this protease alone is capable of in-
ducing these physiological changes.
Next, we wanted to determine whether purified GelE could
activate PAR2. We incubated GelE with Caco-2 cells for 1 h. The
duration of the exposure of Caco-2 cells to GelE was based on the
influence of CCM from E. faecalis V583 on PAR2 detection over
time (see Fig. S5 in the supplemental material). Exposure of this
epithelial cell line to GelE resulted in the elimination of PAR2
detection by Western blotting (Fig. 7). Given that the anti-PAR2
antibody we used recognizes the N-terminal end of the receptor
(amino acids 1 to 100) and that PAR2 is cleaved at the extracellular
































E. faecalis CCM 
PAR2 antagonist 
- + - + 
- - + + 
* 
* 
FIG 3 E. faecalis V583 mediates monolayer permeability via PAR2. Caco-2 cell
monolayers were incubated with or without a PAR2 antagonist (FSLLRY-
NH2) for 24 h. The monolayers were then incubated with E. faecalis V583 CCM
(filled bars) or a medium control (open bars) for a further 24 h. The flux of
FITC-dextran across Caco-2 cell monolayers was significantly greater when
monolayers were cultured with E. faecalis V583 CCM than with the control (*,
P 	 0.0001). The E. faecalis V583 CCM-mediated permeability of Caco-2 cell
monolayers was significantly reduced when PAR2 activation was blocked with
an antagonist (*, P 	 0.0001). Each experimental group represents at least 3
independent experiments with 2 technical replicates in each experiment. Data












































































E. faecalis V583 
FIG 4 The E. faecalis V583 CCM-induced change in the permeability of the
mouse colonic epithelium is absent in PAR2/ mice. (A) The colonic epithe-
lia of WT mice were exposed to CCM from E. faecalis V583 (filled bars), and
the flux of FITC-dextran (paracellular permeability) was measured using
Ussing chambers following 2 h of exposure. E. faecalis V583 CCM increased
the flux of FITC-dextran across the epithelia from WT mice over that of the
control (PBS) (open bars) (P 	 0.04). (B) CCM from E. faecalis V583 could not
induce a change in permeability in mice lacking the PAR2 receptor. Each bar
represents experimental results for 10 WT or 5 PAR2/ mice. Data are ex-
pressed as mean values  standard errors. Comparisons were made using the
nonparametric Mann-Whitney test.
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further suggests that, in addition to increasing permeability, E.
faecalis V583 GelE activates PAR2.
Human fecal proteases from UC patients induce permeabil-
ity in the mouse colonic epithelium via PAR2. We next investi-
gated whether fecal supernatants generated from a human source
(healthy individuals or IBD patients), which harbor a complex
mixture of human and microbial proteases, can induce colonic


















































FIG 6 GelE from E. faecalis V583 induces permeability in epithelial cell mono-
layers. Caco-2 (A) and T-84 (B) cell monolayers were incubated with GelE
purified from E. faecalis V583 (filled bars). The flux of FITC-dextran across
monolayers (indicative of paracellular permeability) was significantly greater
when monolayers were apically (Caco-2) or basally (T-84) cultured with GelE
from E. faecalis V583 for 24 h than when monolayers were cultured with the
medium control (open bars) (*, P 	 0.0001). Each experimental group repre-
sents at least 3 independent experiments with 2 technical replicates in each
experiment. Data are expressed as mean values  standard errors. Compari-








FIG 5 GelE purified from E. faecalis V583 exhibits caseinolytic activity. (A) Putatively isolated GelE was run on an SDS gel to confirm its size and purity. The
isolated protein had a molecular mass of approximately 38 kDa. (B) The putatively purified GelE exhibited caseinolytic activity following overnight incubation
on agar plates containing 2.5% skim milk. These data demonstrate that purified GelE retained its functional activity. (C) Alignment of the 27 digested fragments
of the putative GelE protein generated by LC–MS-MS. All digested fragments aligned with GelE from E. faecalis V583, confirming the identity of this protein. The
shaded sequence indicates the areas homologous to digested fragments. Blue lines represent digested fragments.
Caco-2 
Control 
45 kDa - PAR2 
Control Control 
GelE GelE GelE 
42 kDa - β-actin 
FIG 7 GelE from E. faecalis V583 activates PAR2 on epithelial cells. GelE was
incubated with Caco-2 cells for 1 h. Antibodies could not detect PAR2 in
epithelial cells exposed to GelE. Antibodies for -actin demonstrated equal
loading of proteins in each lane. This blot represents results from at least 3
independent experiments with 2 technical replicates in each experiment.
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permeability was observed in the colonic epithelia from WT mice
exposed to fecal supernatants from UC patients (n  7), and that
increase in permeability was reduced when PAR2 was absent from
the epithelium (Fig. 8A and B). The permeability of mouse colonic
epithelia induced by fecal supernatants from UC patients was re-
duced in the presence of protease inhibitors (Fig. 8C). A subset of
supernatants (n  4) was used, because 3 of the 7 supernatants
from UC patients did not produce sufficient volume to be in-
cluded in all 3 experiments. These data suggest that fecal proteases
from UC patients can induce permeability in the colonic epithe-
lium via PAR2.
DISCUSSION
The intestinal epithelial barrier is made up of a single layer of cells
that provides a first line of defense against infection. Although the
initiating events of intestinal diseases such as IBD and IBS have
not been fully defined, one potential mechanism involves disrup-
tion of the intestinal epithelial barrier and exposure of a geneti-
cally defective mucosal immune system to enteric luminal anti-
gens. Host factors, including proteases and cytokines, can regulate
barrier function (44, 45); however, it is possible that host and
microbial factors can synergistically modulate the intestinal bar-
rier. The relationship between the intestinal microbiota and fecal
protease activity has been reported previously (46), yet the func-
tional impact of enteric microbial proteases on host enteric epi-
thelial receptors is relatively unexplored. We therefore sought to
demonstrate that an enteric protease-secreting microbe could ac-
tivate specific intestinal epithelial receptors leading to permeabil-
ity. The genus Enterococcus encompasses protease-secreting spe-
cies and is reported to be enriched in patients with IBD (47).
Additionally, the mucosal densities of E. faecalis, a species within
this genus, have been shown to correlate positively with clinical
activity indices and sigmoidoscopy scores in UC patients (48). The
enteric microbe E. faecalis has been shown previously to circum-
vent the defense of the intestinal epithelial barrier directly through
proteolytic degradation of an adherence junction protein (E-cad-
herin) and to contribute to intestinal inflammation in the IL-10-
deficient mouse model of colitis (27). Thus, this organism was
chosen as a representative enteric protease-secreting microbe to
demonstrate a proof of principle that a microbial protease can
impact the physiology of the host intestinal epithelium. Here we
report a novel mechanism whereby this microbe, E. faecalis V583,
can alter the intestinal epithelial barrier by the regulation of para-
cellular permeability via gelatinase secretion and PAR2 activation.
In the gastrointestinal (GI) tract, PARs can be activated by
endogenous proteases secreted by the pancreas and mast cells, and
potentially by the luminal enteric microbiota, resulting in perme-
ability of the intestinal epithelium (49). Given that increased in-
testinal permeability is a hallmark of IBD and that PAR expression
on the gut epithelium differs between IBD patients and healthy
individuals (50, 51), it is possible that these receptors are involved
in enteric microbial protease-mediated permeability of the intes-
tine. Although the activation of PAR1, -2, and -4 isoforms has
been linked to intestinal permeability (25, 52), increased intestinal
permeability induced by PAR2 has been reported to occur via
disruption of the tight junctions (T-Js) between epithelial cells
(paracellular permeability). Additionally, blocking the activation
of PAR2 was shown to be protective in an experimental model of
colitis (53). Thus, we chose to focus our study on the role of PAR2
in enteric microbial protease-mediated paracellular permeability.
Indeed, we found that a PAR2 antagonist inhibits the E. faecalis
CCM-mediated change in the permeability of epithelial cell
monolayers, suggesting a role for this receptor in this process.
PARs are activated via cleavage of their N termini, resulting in
intracellular signaling (54). Since the anti-PAR2 antibody used in
this study recognizes the N terminus of the receptor, and since
PAR2 detection was lost upon exposure of epithelial cell mono-
layers to E. faecalis V583 CCM over time, we conclude that se-
creted proteins from this enteric microbe result in the activation
of PAR2. Using purified gelatinase and Western blotting, we fur-
ther demonstrated the ability of this protease to activate PAR2.
Taken together, these data highlight a role for secreted gelatinase














































































































FIG 8 The permeability of the epithelium mediated by fecal supernatants from UC patients is lost in PAR2/ mice. The colonic epithelia of mice were exposed
to fecal supernatants generated from UC patients, and permeability was measured using Ussing chambers. (A) Exposure of the colonic epithelia of WT mice to
supernatants from UC patients (n  7) for 2 h induced a significant 2-fold increase in paracellular permeability over that of controls (P 	 0.05). (B) Exposure
of the colonic epithelia of PAR2/ mice to supernatants from UC patients (n  7) for 2 h did not exhibit a significant difference in paracellular permeability from
controls. (C) Exposure of the colonic epithelia of WT mice to a subset of supernatants from UC patients (n  4) for 2 h induced a reduced level of paracellular
permeability when these supernatants were incubated with protease inhibitors. Comparisons were made using the nonparametric Mann-Whitney test.
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epithelial cells via PAR2 activation. Given their association with
intestinal permeability, it is possible that the PAR1 and -4 iso-
forms could also play a role in regulating the microbial protease-
mediated permeability of enteric epithelial cells, a potential mech-
anism that warrants further investigation.
Our in vitro and ex vivo data highlight the ability of a colito-
genic enteric microbe to induce intestinal epithelial permeability
via PAR2 activation. In order to determine whether proteases se-
creted from a complex microbial community of human origin are
able to induce the same physiological changes in the intestinal
epithelium, we investigated fecal supernatants from a cohort of
UC patients. It has been reported previously that fecal proteases
from UC patients increase intestinal permeability via PAR4 (24);
however, our findings suggest that proteases from UC patients can
also contribute to increased permeability of the colonic epithe-
lium via PAR2. Although the proteases in the fecal supernatants
analyzed likely originate from both human and microbial sources,
on the basis of our data, we speculate that there may be multiple
enteric microbe-secreted proteases that can alter epithelial perme-
ability via the activation of PARs or by alternative, yet undefined
molecular mechanisms.
Although it has been reported that different mammalian and
prokaryotic proteases can activate PARs (e.g., human trypsin [55,
56] or Porphyromonas gingivalis gingipains [57]), different forms
of these receptors exhibit specificities for various activating pro-
teases (e.g., PAR2 can be activated by trypsin but not by throm-
bin). Additionally, most studies investigating how microbes dis-
rupt the intestinal epithelium via PAR activation have focused on
pathogens. Our study demonstrates that gelatinase secreted into
the gut by a commensal microbe is also capable of activating
PAR2. Gelatinase from E. faecalis has been reported as the princi-
pal mediator of pathogenesis in endocarditis (58) and a significant
contributor to biofilm development (59); thus, we report a novel
mechanism for this microbial protease that may extend to other
enteric microbial proteases and may be a relevant risk factor for
intestinal diseases.
In summary, we report a novel mechanism by which bacterial
proteases from a commensal inhabitant of the intestinal microbi-
ota can disrupt the enteric epithelial barrier. Given that elevated
protease activity has been found in UC patients and dysbiosis has
been established in IBD, our data suggest a possible mechanism
whereby proteases from a dysbiotic intestinal microbiota may in-
crease the permeability of the enteric epithelium and lead to in-
flammation. Since increased intestinal permeability is prevalent in
IBD patients and their apparently healthy first-degree family
members (1, 8), our study highlights gelatinase from E. faecalis,
and by extension gelatinase from other protease-secreting enteric
microbes, as a potential target for therapeutic agents used for the
prevention of intestinal inflammation or the maintenance of re-
mission. PAR activation is known to regulate the T-Js of epithelial
cells (49), and gelatinase from E. faecalis has been shown previ-
ously to disrupt the epithelial barrier directly through proteolytic
degradation of E-cadherin (27). Since we have shown that gelatin-
ase can activate PAR2, and since E-cadherin lies below epithelial
T-Js, it is speculated that gelatinase may disrupt epithelial T-Js via
PAR2 activation, which, in turn, exposes E-cadherin to gelatinase
and further contributes to epithelial barrier disruption. This
model will need to be delineated in future mechanistic studies
investigating this interesting phenomenon.
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